Lilly(Eli) EBIT

The latest EBIT for LLY is $34B as of June 2026. That compares with $18B in the prior-year period — up 88.9% year over year. That is above the Healthcare sector average of $22B. Investors often review this figure alongside Lilly(Eli)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, LLY's EBIT moved from $18B to $34B — a 88.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lilly(Eli)'s operating scale or balance-sheet position.

Against Healthcare companies, LLY currently prints $34B for EBIT, while the sector average sits near $22B. That is roughly 49.8% above the sector mean. Large gaps often invite a closer look at Lilly(Eli)'s growth, margins, and balance sheet.

A EBIT figure of $34B for LLY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting LLY's EBIT ($34B), review year-over-year change from $18B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.